Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA7 | P43166 | 2/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16477917 | 0.83 | CA12 (0.68) | CA12CA2CA7CA14CA1 | |
| SCHEMBL813026 | 0.83 | CA2 (0.68) | CA12CA2CA7CA14CA1 | |
| SCHEMBL6534021 | 0.83 | CA12 (0.68) | CA12CA2CA7CA14CA1 | |
| SCHEMBL2112943 | 0.81 | CA2 (0.65) | CA12CA2CA7CA14CA1 | |
| SCHEMBL4901848 | 0.79 | CA2 (0.64) | CA12CA2CA7CA14CA1 | |
| SCHEMBL1706621 | 0.78 | CA2 (0.68) | CA12CA2CA7CA14CA1 | |
| SCHEMBL6055917 | 0.78 | CA12 (0.52) | CA12CA2CA7CA14CA1 | |
| Benzyl(Benzylsulfamoyl)Amine SCHEMBL2298224 | 0.78 | CA12 (1.00) | CA12CA2CA7CA14CA1 | |
| SCHEMBL24990593 | 0.76 | CA12 (0.59) | CA12CA2CA7CA14CA1 | |
| SCHEMBL11690253 | 0.76 | CA12 (0.59) | CA12CA2CA7CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032522-A1 | Antiviral agents | VIROBAY, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007005779-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032522-A1 | Antiviral agents | MAVS, HAVCR2, EIF2AK2 | CA12 4464/4885CA2 4345/4885CA7 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.